Descovy

FTC/TAF emtricitabine/tenofovir alafenamide

Recommended as a component of initial regimen for most people
Nucleoside "Nuke"

Standard Dose

One tablet once daily, without regard to food. Tablet contains 200 mg emtricitabine and 25 mg tenofovir alafenamide (TAF). For adults and children weighing at least 55 pounds (25 kg), or 77 pounds (35 kg) if taking Descovy with a boosted protease inhibitor. Must be taken in combination with another antiretroviral(s) that does not contain the medications in this drug combination.

Take a missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Descovy’s prescribing information indicates that it should not be used if CrCl is less than 30 mL/min, but data have shown that it can be used safely in patients with end stage renal disease on hemodialysis and with CrCl less than 15 mL/min. Descovy was approved for HIV prevention (pre-exposure prophylaxis, or PrEP) in October 2019; see “Descovy for PrEP” page.
  • See the individual drugs contained in Descovy: Emtriva (TAF is not available separately for HIV, but is used to treat hepatitis B under the brand name Vemlidy).
  • See package insert for more complete information on potential side effects and interactions.

Manufacturer

Gilead Sciences, Inc.
gilead.com; descovy.com
(800) GILEAD-5 (445–3235)

AWP

$2,316.85/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments